What is the revenue and EPS growth rate for Evaxion year over year?

What is Evaxion's gross profit margin?

What guidance did Evaxion's management provide for the next earnings period?

What were the key takeaways from Evaxion’s earnings call?

Did Evaxion beat or miss consensus estimates last quarter?

What does Evaxion do and what are its main business segments?

What is the market's earnings forecast for Evaxion next quarter?

What is Evaxion's latest dividend and current dividend yield?

- **Clinical Breakthroughs**: EVX-01 melanoma vaccine shows 75% ORR with 81% T-cell response rate; EVX-04 AML vaccine targets novel ERV antigens. 
- **Financial Strength**: $23M cash runway to H2 2027; reduced net loss to $7.7M with improved operational efficiency. 
- **Strategic Expansion**: AI-Immunology platform enters autoimmune space; EVX-B2 gonorrhea vaccine attracts partner interest post-MSD evaluation. 
- **2026 Milestones**: Submit EVX-04 IND, share EVX-01 3-year data, and advance autoimmune platform development.

**【CEO Summary Section】**
- **2025 Milestones**: Achieved significant progress in collaborations (MSD, Gates Foundation), advanced R&D programs (EVX-01, EVX-04), and extended cash runway to H2 2027. 
- **EVX-01 Success**: Presented 2-year Phase II data showing 75% ORR in melanoma, with 81% antigen-specific T-cell response rate. 3-year data and biomarker updates expected in 2026. 
- **New Therapeutic Areas**: Expanded AI-Immunology platform into autoimmune diseases, targeting unmet needs in chronic conditions. 
- **Partnership Strategy**: Actively engaging with pharma partners to leverage platform for infectious disease and oncology assets, e.g., EVX-B2 (gonorrhea) and EVX-04 (AML). 

**【CFO Financial Commentary】**
- **2025 Cash Inflows**: $32M from public offerings, MSD exercise fee, and warrant exercises. 
- **Financial Health**: Reduced net loss to $7.7M (vs. prior year), improved operational efficiency, and strengthened equity position. 
- **Runway**: $23M cash balance as of year-end, supporting operations and pipeline development. 

**【Q&A Highlights】**
- **EVX-04 Clinical Pathway**: Planning regulatory submission for AML vaccine in H2 2026, with preclinical data showing tumor growth inhibition. 
- **EVX-01 Partnering**: High interest from pharma due to 81% T-cell hit rate and advanced melanoma data; 3-year durability data to be shared later in 2026. 
- **AI-Immunology in Autoimmune**: Early-stage validation underway, focusing on prevalent diseases with strong immunological components. 
- **MSD Collaboration**: MSD extended evaluation of EVX-B2 due to data strength; Evaxion retains full rights and sees partner interest. 
- **Strategic Focus**: Balancing internal clinical development with external partnerships to maximize asset value and accelerate timelines.

Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript

- **MSD Deal Boosts Liquidity**: $7.5 million option exercise extends cash runway to mid-2027, with potential $592 million in future milestones.
- **EVX-01 Clinical Success**: 75% objective response rate at two years, validating AI-driven neoantigen vaccine approach.
- **Innovative AML Program**: EVX-04 targets shared ERV antigens, offering a novel off-the-shelf cancer vaccine strategy.
- **New CEO Leadership**: Dr. Helen Tayton-Martin's appointment signals strategic focus on partnerships and pipeline advancement.

**【Management Updates】**
- **New CEO Appointment**: Dr. Helen Tayton-Martin will assume the role of CEO on November 24, 2025, bringing extensive biotech leadership experience. Interim CEO Birgitte Rono will revert to her role as Chief Scientific Officer.
- **MSD Deal Milestone**: MSD exercised its $7.5 million option on EVX-B3, extending the company's cash runway to mid-2027. The evaluation period for EVX-B2 has been extended, with a decision expected in early 2026.

**【R&D and AI-Immunology Highlights】**
- **EVX-01 Phase II Data**: Presented two-year clinical data showing a 75% objective response rate, with 11/12 responders maintaining responses at two years. EVX-01 induced neoantigen-specific T cell responses in all patients, with 81% of vaccine neoantigens demonstrating immunogenicity.
- **EVX-04 Launch**: Introduced a novel therapeutic cancer vaccine targeting endogenous retrovirus (ERV) antigens in acute myeloid leukemia (AML), leveraging the AI-Immunology platform for shared, off-the-shelf antigens.
- **AI Platform Innovation**: Launched an automated vaccine design module reducing development time and costs, enabling seamless transition from target discovery to production.

**【Financial Results】**
- **Revenue**: Q3 revenue included the $7.5 million MSD payment, with potential future revenue of up to $592 million if MSD exercises further options.
- **Cash Position**: Cash balance of $10.6 million at quarter-end, with additional funding from warrant exercises and debt conversions.
- **Cost Management**: Operating expenses remained stable year-over-year, with a focus on maintaining financial discipline.

**【Q&A Highlights】**
- **Partnership Strategy**: Active discussions with multiple partners across oncology and infectious disease programs, with interest in both vaccine candidates and AI platform collaborations.
- **EVX-B2 Update**: MSD is conducting confirmatory studies, with a decision on the $2.5 million option expected in early 2026.
- **Platform Monetization**: Exploring opportunities to license the automated design module to third parties for antigen manufacturing optimization.

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

- **MSD Partnership Progress:** Option exercise decision expected by end-2025, with collaboration on track for data readouts.
- **Gates Foundation Grant:** Risk-free polio vaccine development underway, enhancing platform visibility.
- **Financial Strength:** $14.7 million cash runway extended to mid-2026 via loan-to-equity conversion.
- **Pipeline Momentum:** EVX-B4 GAS vaccine and EVX-V1 CMV vaccine advancing in preclinical stages; 2-year EVX-01 data pending at ESMO 2025.

**【Management Opening Remarks】**
- Interim CEO Birgitte Rono highlighted Q2 achievements, including progress with MSD partnership and Gates Foundation grant for polio vaccine development.
- Emphasized strong R&D pipeline across oncology (EVX-01) and infectious diseases (EVX-B4, EVX-V1), with cash runway extended to mid-2026.
- Noted challenges in deal execution due to financial market and regulatory uncertainties.

**【R&D Updates】**
- **EVX-01 (Cancer Vaccine):** 2-year clinical data to be presented at ESMO 2025; Phase II extension phase underway to assess standalone efficacy without pembrolizumab.
- **EVX-B4 (GAS Vaccine):** New program targeting Group A Streptococcus, with AI-Immunology identifying novel antigens for preclinical testing.
- **EVX-V1 (CMV Vaccine):** Preclinical development progressing, with AI-Immunology designing multi-component antigens for broad viral targeting.
- **Polio Vaccine:** Gates Foundation grant enables risk-free platform application, with potential for future collaborations.

**【Financial Commentary】**
- **Cash Position:** $14.7 million at end of Q2, supporting operations until mid-2026.
- **Equity Strengthening:** Conversion of $4.1 million loan from European Investment Bank to equity, reducing liabilities.
- **Operating Loss:** $4.3 million (Q2 2025) vs. $4.6 million (Q2 2024), with R&D costs expected to rise in H2.
- **Net Loss:** $4.8 million (Q2 2025) driven by reduced financial expenses compared to prior year.

**【Q&A Highlights】**
- **MSD Partnership:** Decision on option exercise expected in H2 2025; collaboration progressing as planned with promising data.
- **Business Development:** Active discussions across oncology and infectious disease pipelines, with focus on AI-Immunology collaborations.
- **ESMO Data:** 2-year EVX-01 results pending; 11 patients remain active in trial, with extension phase evaluating vaccine alone.

Evaxion Biotech A/S (EVAX)-14 Aug 25-2025 Q2 Earnings call transcript

- **Merck Option Exercise Catalyst**: Potential $10M H2 2025 milestone for EVX-B2/B3 compounds.
- **EVX-01 Immunogenicity**: 80% target immune response rate, CD4 T-cell dominance, and CD8 response in half of patients.
- **Financial Strength**: $17.8M cash (mid-2026 runway) and $10.3M equity, meeting NASDAQ requirements.
- **Pipeline Momentum**: ERV vaccine lead selection in H2, first infectious disease candidate shortlisted.
- **Market Risk**: Macro uncertainty delays 2025 deal execution, though two-deal target remains intact.


**【CEO Opening Remarks】**
- Q1 2025 highlights: Strong progress across business development, R&D, and financial execution.
- Key milestone: Potential $10M from Merck option exercise in H2 2025 for EVX-B2/B3 compounds.
- Business development pipeline remains solid, targeting at least two new deals in 2025, though macro uncertainty poses risks.
- EVX-01 Phase 2 trial extension dosing begins, with two-year readout expected in H2.
- Precision ERV cancer vaccine lead candidate selection on track for H2.
- Cash runway extended to mid-2026, supporting key 2025 milestones.

**【CSO R&D Update】**
- EVX-01 Phase 2 data: 80% of vaccine targets elicited immune response (vs. lower rates in peers), with CD4 T-cell dominance and CD8 response in ~50% patients.
- Trial extension to assess monotherapy efficacy, with minimal incremental cost.
- ERV vaccine progress: Lead candidate design optimized for broad HLA coverage, with IND/CTA prep underway.
- Infectious disease pipeline: First bacterial target shortlisted post-expert review, with second candidate to be added in H2.

**【CFO Financial Review】**
- Q1 2025 cash position: $17.8M (vs. $6M at year-end 2024), driven by capital market activities.
- Operating loss: $3.9M (down 11% YoY), with $14M annual cash burn forecast.
- Financial income: $2.4M from derivative liability reassessment, with 50% of warrants remaining to be marked-to-market.
- Equity: $10.3M (vs. NASDAQ listing requirements met), with no immediate listing risk.
- Mid-2026 cash runway supports key 2025 milestones, plus potential $10M from Merck in 2025.

**【Q&A Key Takeaways】**
- EVX-01 immune profile: CD4 T-cell dominance reflects peptide vaccine mechanism, with CD8 response variability.
- ERV vaccine strategy: Initially standalone, precision vaccine targeting shared antigens for broader patient access.
- Gonorrhea vaccine context: UK trial highlights unmet need, aligning with EVX-B2's potential for broader protection.
- Merck collaboration: No direct feedback on UK trial, but reinforces commercial rationale for EVX-B2/B3 pipeline.


Actual	-11.5	-18	-13.5	-19.5	-12.5	-10	-12	-14.5	-12	-10.5	-10.5	-8	0.15	-0.6	-0.2	-0.07	-0.01		0.01	-0.02
Forecast	-15	-14.6667	-16.8333	-14.6667	-16.3333	-15	-13.3333	-13.1667	-13	-10.75	-9.5	-8	-5.475	-1.2667	-1.5667	-1.955	-0.705		-0.01	-0.245
Surprise	+23.33%	-22.73%	+19.80%	-32.95%	+23.47%	+33.33%	+10.00%	-10.13%	+7.69%	+2.33%	-10.53%	0.00%	+102.74%	+52.63%	+87.23%	+96.42%	+98.58%	0.00%	+200.00%	+91.84%

Actual	0	0	0	0	0	0	0	0	0	0	0	73.00K	51.00K	154.00K	3.02M	122.00K	0	--	7.49M	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	37.00K	52.00K	123.33K	1.66M	60.00K	--	3.75M	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+37.84%	+196.15%	+2346.22%	-92.65%	-100.00%	0.00%	+99.79%	0.00%

EVAX

EVAX fundamentals

EVAX Q4 2025 Earnings

Earnings Call

You can ask Aime

EVAX

EVAX fundamentals

EVAX Q4 2025 Earnings

Earnings Call

EVAX Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

EVAX Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

EVAX Earnings Call Summary for Q2/20258:30 AM on Aug 14, 2025

EVAX Earnings Call Summary for Q1/20258:30 AM on May 27, 2025

EVAX Earnings Call Summary for Q4/2024 Apr 2, 2026

You can ask Aime